Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy—findings from clinical practice

PURPOSE: Clinical practice adherence to current guidelines that recommend primary prophylaxis (PP) with granulocyte colony-stimulating factors (G-CSFs) for patients at high (≥20 %) overall risk of febrile neutropenia (FN) was evaluated. METHODS: Adult patients with breast cancer, non-small cell lung...

Descripción completa

Detalles Bibliográficos
Autores principales: Krzemieniecki, K., Sevelda, P., Erdkamp, F., Smakal, M., Schwenkglenks, M., Puertas, J., Trojan, A., Szabo, Z., Bendall, K., Maenpaa, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913845/
https://www.ncbi.nlm.nih.gov/pubmed/24154740
http://dx.doi.org/10.1007/s00520-013-2021-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913845/
https://www.ncbi.nlm.nih.gov/pubmed/24154740
http://dx.doi.org/10.1007/s00520-013-2021-2

Ejemplares similares